Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Brief: Biosite Diagnostics/Scios

This article was originally published in The Gray Sheet

Executive Summary

Biosite Diagnostics/Scios: Diagnostic test manufacturer Biosite gains license to utilize biopharmaceutical developer Scios' B-type natriuretic peptide detection technology in its point-of-care congestive heart failure diagnostic. The agreement calls for Biosite to pay licensing fees and product royalties to Scios, terms of which were not disclosed. San Diego-based Biosite also signed an identical deal with biopharmaceutical firm XOMA Corp., giving it access to XOMA's lipopolysaccharide binding protein technology for sepsis detection...

You may also be interested in...



Biosite/Xoma

Biopharmaceutical firm Xoma alleges San Diego-based Biosite Diagnostics breached its obligations under three license agreements relating to bacterial expression of antibodies. Biosite says it believes it is in "full compliance" with the agreements, signed in 1997, and that Xoma is seeking to renegotiate terms of the license agreements (1"The Gray Sheet" March 17, 1997, I&W-17)

'Purple Drank' Drug Cocktail Linked To France's Latest Reverse-Switch

Promethazine has been reverse-switched from OTC to prescription status in France, with rising abuse of the drug in the so-called Purple Drank cocktail one of the motivating factors for the move by the country's health ministry.
UsernamePublicRestriction

Register

MT007710

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel